National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

indium In 111 CHX-A DTPA trastuzumab
An indium I 111-labeled trastuzumab with potential use as an imaging agent. Indium In 111 CHX-A DTPA trastuzumab is chemically conjugated via a bifunctional metal chelator molecule, 2-(p-isothiocyanatobenzyl)-cyclohexyl-diethylenetriaminepentaacetic acid (CHX-A DTPA), a backbone-substituted derivative of DTPA. This agent may allow radioimmunolocalization of HER2-positive cells. Trastuzumab, a recombinant humanized monoclonal antibody that selectively binds with high affinity to the extracellular domain of human epidermal growth factor receptor 2 (HER2), may elicit an antibody-dependent cellular cytotoxicity (ADCC) against tumor cells that overexpress HER2. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)




Previous:indicine-N-oxide, indinavir sulfate, indium I 111 bevacizumab, indium I 111 chimeric monoclonal antibody G250, indium In 111 chimeric monoclonal antibody 806
Next:indium In 111 ibritumomab tiuxetan, indium In 111 monoclonal antibody BrE-3, indium In 111 monoclonal antibody huPAM4, indium In 111 pentetate, indium In 111-CMD-193

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov